ASP Isotopes Inc

ASP Isotopes (ASPI) develops quantum laser-based enrichment technology to produce isotopes for nuclear fuel, medical applications, and quantum computing materials. Its process uses precisely tuned lasers to separate isotopes like Uranium-235 and HALEU more efficiently than traditional centrifuges, targeting lower costs and higher purity. In the nuclear renaissance, ASPI aims to address fuel supply bottlenecks for small modular reactors and advanced designs, positioning itself as a key enabler for scaling low-carbon nuclear power amid rising demand from tech giants and utilities.

In the past 12 months, ASPI commenced commercial Carbon-14 production at its South Africa facility in March 2024, signed an MOU with TerraPower in July for potential HALEU supply, and advanced plans for a U.S. uranium enrichment plant with $12 million in funding. Key risks include unproven scalability of laser tech, regulatory delays for nuclear licenses, high capital needs leading to dilution, and competition from established players like Centrus Energy.

AI-generated brief · refreshed 1 day ago